Chromatic Pupillometry to Assess the Melanopsin-Light Pathway in Progressive Supranuclear Palsy (PMPSP)
Functional Assessment of the Melanopsin-Containing Retinal Ganglion Cells in Progressive Supranuclear Palsy Using Chromatic Pupillometry
Sponsor: Massachusetts General Hospital
Listed as NCT03330353, this observational or N/A phase trial focuses on AD - Alzheimer's Disease and ALS (Amyotrophic Lateral Sclerosis) and remains ongoing. Sponsored by Massachusetts General Hospital, it has been updated 7 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status
-
Dec 2019 — Jan 2021 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jun 2018 — Dec 2019 [monthly]
Recruiting
▶ Show 2 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
-
Dec 2017 — Apr 2018 [monthly]
Recruiting NA
First recorded
Nov 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Massachusetts General Hospital
- NeurOptics Inc.
- University of Toronto
For direct contact, visit the study record on ClinicalTrials.gov .